Adds background in paragraphs 2,3 and FDA comment in paragraph 4
Nov 27 (Reuters) - The U.S. Food and Drug Administration is weighing the need for a regulatory action on bluebird bio's BLUE.O gene therapy for a rare neurological disorder, it said on Wednesday, as the agency probes additional reports of blood cancers from its use.
Skysona was approved by the FDA in 2022 for the treatment of cerebral adrenoleukodystrophy.
The therapy's prescribing information included a warning for blood cancers, including leukemia and myelodysplastic syndromes, which are a group of cancers that occur when the bone marrow produces immature blood cells instead of healthy ones.
The FDA said considering the risk of such cancers, patients should consider alternative therapies.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。